The U.S. Food and Drug Administration (FDA) accepts Reynolds American Inc. (RAI) modified risk tobacco product (MRTP) applications for six styles of Camel Snus, according to a company press release.
The smokeless premium pouched tobacco product filing is now under substantive review. If approved by the FDA, the company will market and advertise the product as a modified risk tobacco product (MRTP). The advertising would “indicate a differential in risk for smokers who switch completely to Camel Snus from cigarette smoking”, according to the company press release.
The review process will also incorporate an assessment by the Tobacco Products Scientific Advisory Committee (TPSAC) and public commentary. A modified version of the applications will be made available to the public.
Dr. James Figlar, senior vice president, scientific & regulatory affairs for RAI Services Company was quoted as saying “FDA’s acceptance and filing for review of these MRTP applications for Camel Snus is an important step forward in fulfilling RAI’s commitment to collaborative leadership in the transformation of the tobacco industry.”